Diabetes & Endocrinology – Page 2

Veligrotug Delivers Rapid, Durable Benefit in Active Thyroid Eye Disease in the Phase 3 THRIVE Trial

By MedXY 06/06/2026

In phase 3 testing, veligrotug produced rapid and clinically meaningful reductions in proptosis, diplopia, and disease activity in active thyroid eye disease, with durable benefit through 52 weeks and a favorable short-term safety profile.

Diabetes & Endocrinology news

Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult Hypothyroidism

By MedXY 06/05/2026

A Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.

Diabetes & Endocrinology news Oncology

Early HbA1c Control After Type 2 Diabetes Diagnosis May Shape Long-Term Cancer Risk

By MedXY 06/05/2026

In a large Hong Kong cohort with newly diagnosed type 2 diabetes, higher early HbA1c exposure was associated with greater long-term cancer risk, suggesting that glycaemic control soon after diagnosis may matter more than later improvement.

Diabetes & Endocrinology news Public Health

Food Coloring Additives Linked to Higher Type 2 Diabetes Risk in a Large French Cohort

By MedXY 06/05/2026

A large French cohort study found that higher exposure to several food coloring additives was associated with increased incidence of type 2 diabetes, highlighting the need for further research and possible reevaluation of some additives.

Diabetes & Endocrinology news Ophthalmology

No Signal for Increased Neovascular AMD Risk With Semaglutide in Adults With Type 2 Diabetes: Interpretation of a Large OHDSI Network Study

By MedXY 06/04/2026

A multinational OHDSI network analysis found no meaningful association between semaglutide use and neovascular age-related macular degeneration among adults with type 2 diabetes across cohort and self-controlled designs.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Long-Term Risk of Hypothyroidism After Thyroid Abnormalities Identified in Pregnancy

By MedXY 06/04/2026

Thyroid abnormalities found during pregnancy, especially when subclinical hypothyroidism and TPO antibodies coexist, can signal a much higher long-term risk of overt hypothyroidism, supporting ongoing thyroid follow-up after delivery.

Diabetes & Endocrinology news Oncology

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin

By MedXY 06/03/2026

In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.

Diabetes & Endocrinology news

Beta Cell Glucose Sensitivity May Predict Response to New-Onset Type 1 Diabetes Therapies

By MedXY 06/03/2026

A pooled analysis of nine type 1 diabetes trials found that beta cell glucose sensitivity may better predict response to disease-modifying therapy than C-peptide alone, helping identify patients most likely to benefit.

Diabetes & Endocrinology Neurology news

Genetic Evidence Strengthens High BMI as a Causal Driver of Vascular Dementia, With Blood Pressure as a Partial Mediator

By MedXY 06/03/2026

A 2026 Mendelian randomization study supports high BMI as a causal risk factor for vascular-related dementia, with part of the effect mediated through elevated systolic and diastolic blood pressure.

Cardiology Diabetes & Endocrinology news

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

By MedXY 06/03/2026

A validated model, SABRE, estimates who with type 2 diabetes may gain the most heart-failure prevention benefit from SGLT2 inhibitors, enabling more precise, individualized prescribing.

Cardiology Diabetes & Endocrinology news

Thyroid Dysfunction Is a Cardiovascular Risk Multiplier, but Treatment Benefits Depend on Phenotype, Severity, and Age

By MedXY 06/03/2026

Thyroid dysfunction reshapes lipid metabolism, vascular tone, cardiac performance, and rhythm. Cardiovascular risk is clearest at the extremes of thyroid status, while treatment decisions in subclinical disease should remain individualized.

Cardiology Diabetes & Endocrinology news

Visceral Fat Loss, Not Weight Loss Alone, May Be the More Durable Target for Long-Term Cardiometabolic Health

By MedXY 06/03/2026

Long-term follow-up of CENTRAL and DIRECT-PLUS suggests MRI-measured visceral fat loss during lifestyle intervention predicts sustained cardiometabolic benefit and lower future type 2 diabetes risk, even after substantial weight regain.

Diabetes & Endocrinology news

SSTR2 Antagonism Restored Glucagon Responses During Experimental Hypoglycaemia in Adults With Long-Standing Type 1 Diabetes

By MedXY 05/31/2026

In a randomized crossover phase 1 study, the investigational SSTR2 antagonist ZT-01 increased glucagon responses during insulin-induced hypoglycaemia in adults with type 1 diabetes without treatment-related safety signals.

Diabetes & Endocrinology news Pediatrics

In Transition-Age Childhood-Onset GH Deficiency, Glucagon Test Results Reflect Pituitary Damage More Than Body Mass Index

By MedXY 05/31/2026

In 180 adolescents and young adults with childhood-onset GH deficiency, glucagon-stimulated GH secretion was driven mainly by hypothalamic-pituitary disease severity, while BMI had little independent effect after accounting for etiology.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Less Than 5 kg of Gestational Weight Gain in Type 2 Diabetes Was Linked to Lower Risk of LGA, Hypertensive Disorders, NICU Admission, and Cesarean Delivery

By MedXY 05/31/2026

In a retrospective cohort of pregnancies complicated by type 2 diabetes, gestational weight gain under 5 kg was associated with lower odds of several adverse perinatal outcomes without a statistically significant rise in preterm birth or small-for-gestational-age infants.

Diabetes & Endocrinology Internal Medicine news

Two-Year SURPASS-EARLY Findings Show Tirzepatide Outperforms Intensified Conventional Care in Early Type 2 Diabetes

By MedXY 05/30/2026

In adults with early type 2 diabetes inadequately controlled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, body weight, and waist circumference than intensified conventional care, with substantially higher rates of normoglycemia.

Diabetes & Endocrinology news

Tirzepatide Versus Intensified Conventional Care After 2 Years in Early Type 2 Diabetes

By MedXY 05/30/2026

In early type 2 diabetes uncontrolled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, weight, and waist circumference than intensified conventional care, with more patients achieving normoglycemia.

Diabetes & Endocrinology Gastroenterology news

Glycemic Control and Diabetes Outcomes After Surgical Therapy for Diabetic Gastroparesis

By MedXY 05/29/2026

Surgical therapy for diabetic gastroparesis was linked to better long-term HbA1c control, less insulin use, and fewer diabetes-related complications, though mortality was unchanged.

Diabetes & Endocrinology General Surgery news

Marked Preoperative TSH Elevation Signals More Difficult Thyroidectomy in Graves’ Disease

By MedXY 05/28/2026

In a large single-center cohort, Graves’ disease patients with preoperative TSH ≥10.0 μIU/mL had greater blood loss, larger preoperative thyroid enlargement, and longer operations, suggesting that avoiding iatrogenic hypothyroidism during surgical preparation may improve operative conditions.

Cardiology Diabetes & Endocrinology news

Younger Adults With Type 2 Diabetes Show a More Adverse Cardiometabolic Profile Than Older Adults

By MedXY 05/28/2026

Across four national cohorts, younger adults with type 2 diabetes had higher adiposity and triglycerides, while glycemia peaked in midlife and blood pressure and albuminuria rose with age, suggesting age-specific pathways to diabetes complications.